The latest discovery of Johns Hopkins University: antiparasitic drugs can prevent pancreatic cancer!

Pancreatic cancer is the third most deadly cancer in the United States.

In a study published in the journal Oncotarget, Gregory Riggins, MD, professor of neurosurgery and oncology at Johns Hopkins University School of Medicine, his team used two different mouse models to determine anti-parasite resistance The drug mebendazole can slow down or prevent the growth and spread of early and late pancreatic cancer

Riggins said: "We think mebendazole has an effect at all stages

Riggins and his team injected mebendazole into mice that had been genetically modified to develop pancreatic cancer

Mebendazole was originally used to combat roundworm, hookworm and other parasitic infections by cutting off the parasite's nutrient supply.

Riggins said that he hopes to continue his team's research through human clinical trials

Riggins said: "We advocate the use of mebendazole as a treatment for pre-metastasis diagnosis to see if we can slow or prevent pancreatic cancer

references:

"Mebendazole disrupts stromal desmoplasia and tumorigenesis in two models of pancreatic cancer" by Tara Williamson, Michelle Carvalho de Abreu, Dimitri G.